News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Medicare's $4T Shift: 200M Americans Move to AI-Powered Outcome Pay by 2028
Medicare ACCESS, launched December 2025, reimburses on patient outcomes—not visit minutes. 165M lives already committed to switch by 2028. Here's who wins and why fee-for-service shops lose.
Qualtrics buys Press Ganey for $6.75B to predict patient needs
Qualtrics closed its acquisition of Press Ganey Forsta, gaining access to patient data from 41,000+ healthcare facilities. The combined platform aims to shift hospitals from measuring past experiences to predicting patient friction before it happens.
Doctors won't trust AI unless it shows its work, says CMO
Dr. Niki Panich, chief medical officer at Penguin AI, argues physicians need to see exactly how an AI system arrived at a clinical recommendation—not just a confidence score buried in menus.
Two Healthcare IT Conferences Set for May and June 2026
HIMSS26 in Copenhagen (May 19-21) and the AI in Healthcare Forum in Boston (June 25-26) will convene clinicians, executives, technologists, and researchers. Both events feature accredited sessions and hands-on learning tracks.
Indian cardiac hospital hits HIMSS Stage 6 analytics maturity, first in country
Narayana Institute of Cardiac Sciences became the first hospital in India to achieve HIMSS Analytics Maturity Assessment Model Stage 6 validation. The win hinged on treating analytics as a business function, not IT—and building models before perfecting data.
Immunovant's arthritis drug shows 'compelling' results in tough trial
Immunovant's share price jumped on analyst praise for arthritis trial data. The company is advancing a potential treatment for a condition where existing options fall short.
Acceleron Veterans Launch Oorja to Reverse Lung Scarring in Fibrosis
Oorja Biotech emerged from stealth with a peptide drug targeting idiopathic pulmonary fibrosis. The startup is led by former Acceleron executives and claims potential to reverse lung scarring.
Bristol Myers signs Anthropic deal to expand AI across drug development
Bristol Myers Squibb deepens its AI strategy with a new collaboration with Anthropic. The deal marks the pharma giant's latest move to embed large language models across research and operations.
Parabilis seeks IPO after $800M raise to target undruggable diseases
Parabilis Biotech is preparing to go public following an $800M funding round, joining a year when biotech IPOs have averaged $286M in proceeds. The company targets protein-folding diseases conventional drugs cannot address.
Pfizer's 25-valent pneumonia shot outperforms Prevnar 20 in Phase 2
Pfizer's experimental PF-07872412 produced higher antibody titers for serotype 3 than its approved 20-valent vaccine in head-to-head testing. What the data shows and what comes next.
Pharma skips middlemen, builds direct ties to GLP-1 patients
Drug makers are shifting from doctor-gated distribution to direct consumer channels, driven by patient demand for weight-loss GLP-1s. Here is how the industry is reorganizing sales and marketing.
China's first multinational pharma company is five years away
Drew Armstrong, Endpoints News executive editor, predicts a Chinese biopharma firm will achieve true multinational scale within five years. The timeline matters for investors and regulators watching competitive shifts.